Europe Pharmaceutical Warehousing Market Size, Share, Trends and Forecast, 2026-2035 | Cold Chain, ULT Storage and 3PL Growth Propel Market to USD 51.2 Billion

Dublin, Nov. 04, 2026 (GLOBE NEWSWIRE) -- "Europe Pharmaceutical Warehousing Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)" has been added to ResearchAndMarkets.com's offering.

The Europe pharmaceutical warehousing market reached USD 26.8 Billion in 2025 and is projected to grow at a CAGR of approximately 8.3% from 2026 to 2035, reaching USD 51.2 Billion by 2035. According to the report, growth is being supported by rising volumes of temperature-sensitive pharmaceutical products, stricter EU Good Distribution Practice (GDP) compliance requirements, expanding biopharmaceutical production and continued investment in digitally enabled warehouse management systems.

Demand for specialised pharmaceutical storage is increasing as manufacturers develop more biologics, biosimilars, mRNA-based medicines and advanced therapy medicinal products (ATMPs). These products require precise environmental controls, validated handling processes and, in many cases, deep freeze or cryogenic storage. IoT and AI-enabled monitoring systems are also strengthening warehouse performance by improving environmental monitoring, inventory visibility, risk management and regulatory documentation.

Key Market Trends and Insights

• Germany leads the regional market: Germany accounted for approximately 22% of Europe pharmaceutical warehousing revenue in 2025. Its leadership is supported by its position as Europe's largest pharmaceutical manufacturing nation-accounting for 5.2% of global pharmaceutical production-and the presence of major manufacturers such as Bayer , Merck KGaA KGaA, Boehringer Ingelheim and Fresenius Medical Care . These companies require extensive temperature-controlled warehousing capacity for domestic distribution and export logistics.
• Cold chain storage remains the largest segment: The Cold Chain (2-8C) segment generated the highest revenue in 2025. Approximately 80% of pharmaceutical products require temperature-controlled transportation and storage, sustaining demand for compliant refrigerated warehouse space across Europe.
• Ultra-Low Temperature capacity is expanding rapidly: The Deep Freeze and Ultra-Low Temperature (ULT) segments are expected to record the strongest growth through 2035. Demand is being driven by mRNA vaccines, advanced biologics, and cell and gene therapy products requiring storage below -60C.
• Third-Party Logistics outsourcing is accelerating: The Third-Party Logistics (3PL) segment is forecast to be the fastest-growing facility type as pharmaceutical companies increasingly outsource storage and distribution to specialist providers operating certified GDP infrastructure. This approach enables manufacturers to concentrate capital investment on research, production and product development.

European Pharmaceutical Logistics Investment

More than 85% of approved pharmaceutical products in Europe required specific temperature and humidity controlled storage conditions as of October 2024, according to the European Medicines Agency. This regulatory and operational requirement has encouraged investment in GDP-certified temperature-controlled facilities across major pharmaceutical logistics hubs, including Frankfurt, Amsterdam, Basel, London and Brussels.

Europe's pharmaceutical industry invested EUR 44.50 billion in R&D during 2022, supporting a sustained pipeline of innovative medicines with increasingly complex storage requirements. This activity is creating opportunities for pharmaceutical warehouse operators, cold chain logistics providers, technology vendors and specialist 3PL companies.

Belgium has also strengthened its position as an international pharmaceutical logistics hub. The Port of Antwerp became the world's first seaport to receive an official GDP certificate in 2022 and provides 63,000 m of GDP-certified warehouse space for 2-8C and 15-25C storage. Brussels Airport handles approximately 120,000 tonnes of pharmaceutical air freight annually, reinforcing the country's role in global healthcare distribution.

Market Outlook

The EU's Good Distribution Practice guidelines require rigorous environmental monitoring, qualification documentation and cold chain risk management throughout pharmaceutical storage and distribution operations. As compliance expectations evolve, warehouse operators are expected to increase investment in automated systems, real-time monitoring, data analytics and validated temperature-control infrastructure.

The report indicates that long-term market expansion will be shaped by biopharmaceutical production growth, increased 3PL outsourcing, rising demand for Ultra-Low Temperature storage and the digital transformation of pharmaceutical warehouse management. Providers with scalable GDP-certified facilities, strong cold chain capabilities and integrated monitoring technology will be well positioned to capture opportunities through 2035.

Companies Featured

• DHL (Germany)
• DB Schenker (Germany)
• Kuehne + Nagel (Switzerland)
• Ceva Logistics (Switzerland)
• Geodis (France)
• Girteka Group (Lithuania)

For more information about this report visit https://www.researchandmarkets.com/r/s939jj

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: 
CONTACT: ResearchAndMarkets.com 
         Laura Wood, Senior  Press Manager 
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470 
         For U.S./ CAN Toll Free Call 1-800-526-8630 
         For GMT Office Hours Call +353-1-416-8900